In a randomized trial, respiratory illnesses decreased by over 50% in children receiving monthly, oral vitamin D supplementation for 2 years.
Vitamin D's immunomodulatory effects may decrease the risk for respiratory illness and infections. To examine this potential benefit in children with sickle cell disease, researchers randomized 62 patients to receive a monthly, oral high dose (100,000 IU) or standard dose (12,000 IU) of vitamin D for 2 years in a double-blind trial. Participants' age range was 3 to 20 years.
Overall, receipt of monthly oral vitamin D was associated with a reduction of over 50% in the rate of respiratory illnesses during the second year, with similar decreases in each treatment group. Annual rates of respiratory events were also similar between groups. At baseline, the mean 25-hydroxyvitamin D level was in the deficient range at 14.3 ng/mL for the total sampl…
Reviewing Author
DisclosuresConsultant/Advisory BoardEli Lilly and Company; Advisory Council, Eunice Kennedy Shriver National Institute of Child Health and Human Development; Subboard for Adolescent Medicine, American Board of Pediatrics
Grant/Research SupportPatty Brisben Foundation
Editorial BoardsOsteoporosis International; Bone; Journal of Adolescent Health
DisclosuresConsultant/Advisory BoardEli Lilly and Company; Advisory Council, Eunice Kennedy Shriver National Institute of Child Health and Human Development; Subboard for Adolescent Medicine, American Board of Pediatrics
Grant/Research SupportPatty Brisben Foundation
Editorial BoardsOsteoporosis International; Bone; Journal of Adolescent Health